Bristol-Myers Squibb Company (BMY) · page 14 of 197
The slide uses a bar chart to compare the peer average P/E multiple against the BMY acquisition price for Celgene, followed by a callout box highlighting the patent cliff risk.
Activist deck · expose_contradiction · expose_contradiction · dense density
Slide locked Sign in to view
Slide schematic 6/6
callout 1/1 chart 1/1 paragraph 1/1 source-note 1/1 title 2/2
Components 6
primary bar-vertical paragraph source-note action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1